Egalet Corporation (NASDAQ:EGLT) Files An 8-K Other Events

ME Staff 8-k
-
0

Egalet Corporation (NASDAQ:EGLT) Files An 8-K Other Events
Item 8.01 — Other Events.

This report contains forward-looking statements, including statements regarding the Company’s belief regarding Teva’s paragraph IV certification and the Company’s intention to enforce its intellectual property rights. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Statements containing the words “may”, “could”, “would”, “should”, “will”, “believe”, “expect”, “anticipate”, “plan”, “estimate”, “target”, “project”, “intend” and similar expressions constitute forward-looking statements. These forward-looking statements involve a number of risks, uncertainties and other factors, including the outcome of the patent infringement lawsuit; the Company’s ability to successfully enforce its intellectual property rights, and to defend its patents; the potential costs associated with a patent infringement lawsuit; the possible introduction of generic competition to ARYMO ER; and other factors discussed in our public filings, including the risk factors included in the Company’s most recent Annual Report on Form10-K (as supplemented by the Company’s Quarterly Reports on Form10-Q),which may cause the actual results to be materially different from those expressed or implied in the forward-looking statements. The Company does not intend to review or revise any particular forward-looking statement in light of future events.


About Egalet Corporation (NASDAQ:EGLT)

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.